Why COVID-19 trials should be blinded (as any other one)

Authors

  • Rafael Leite Pacheco Centro Universitário São Camilo; Universidade Federal de São Paulo (Unifesp)
  • Ana Luiza Cabrera Martimbianco Centro Universitário São Camilo; Universidade Metropolitana de Santos (UNIMES).
  • Carolina de Oliveira Cruz Latorraca Universidade Federal de São Paulo (Unifesp).
  • Rachel Riera Núcleo de Avaliação de Tecnologias em Saúde, Hospital Sírio-Libanês (NATS-HSL); Universidade Federal de São Paulo (Unifesp).

DOI:

https://doi.org/10.17267/2675-021Xevidence.v2i1.2841

Keywords:

Blinding. Clinical trials. COVID-19.

Downloads

Download data is not yet available.

Downloads

Published

2020-04-01

How to Cite

Pacheco, R. L., Martimbianco, A. L. C., Latorraca, C. de O. C., & Riera, R. (2020). Why COVID-19 trials should be blinded (as any other one). Journal of Evidence-Based Healthcare, 2(1), 25–27. https://doi.org/10.17267/2675-021Xevidence.v2i1.2841

Issue

Section

Concept Articles

Most read articles by the same author(s)